Toripalimab

MADRID — In this video, Toni Choueiri, MD, talked about “a very important study” from China in advanced renal cell carcinoma presented at ESMO Congress.

MADRID — Treatment with toripalimab plus axitinib resulted in significantly longer PFS than treatment with sunitinib in patients with previously untreated advanced kidney cancer, according to a presentation from ESMO Congress.

CHICAGO — The addition of toripalimab to first-line nab-paclitaxel significantly prolonged PFS among patients with PD-L1-positive metastatic or recurrent triple-negative breast cancer, according to results of a phase 3 trial.

In this edition, tumor mutational burden linked to immunotherapy response; toripalimab regimen extends EFS in stage III NSCLC; phase 3 study designed for increasing trial diversity, and more.

A combination of toripalimab and perioperative chemotherapy significantly extended EFS compared with chemotherapy alone among patients with resectable stage III non-small cell lung cancer, according to results of a randomized phase 3 study.

The addition of toripalimab to first-line chemotherapy prolonged PFS and OS among patients with advanced non-small cell lung cancer without EGFR/ALK mutations, according to study results.

The FDA granted orphan drug designation to toripalimab for the treatment of esophageal cancer.

The FDA granted breakthrough therapy designation to toripalimab in combination with chemotherapy for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, according to the agent’s manufacturer.

Adding toripalimab to gemcitabine-cisplatin chemotherapy significantly improved PFS and overall response rates and induced longer-lasting responses than chemotherapy alone as first-line therapy for advanced nasopharyngeal carcinoma.

The FDA granted fast track designation to toripalimab for the first-line treatment of patients with mucosal melanoma, according to a manufacturer-issued press release.